1D·

A treasure discovered

$PME (-2.12%) new addition to the depot!

Key growth figures (FY 2025)

Turnover: AUD 213.0 million (+31.9% year-on-year).
Net profit (after tax): AUD 115.2 million (+39.2%).
EBIT (operating profit): AUD 157.7 million (+40.5%).
Dividend: AUD 0.30 per share (+37.5%).
EBIT margin: 74.0% (increase from 69.5% in the previous year).
Net margin: Approx. 54 %.
Return on equity (ROE): Over 60%, underlining the extremely efficient use of capital.

The first tranche into the zone is in, now with $4519 (-0.08%) and $HIMS (+2.98%) now 3 stocks in the healthcare sector

for all those who are now interested in the share and are also buying:

Please pay attention to the spread, buy between 7;30-8:00 then it is extreme (over 6%)

had a spread of 1.x%, which is ok for an Australian small cap

13.03

PME

Pro Medicus

Bought x10 at €82.60

€826.00

23 Comments

Alpalaka@Alpalaka

What are you going to do with the time you gained because you cut "now" short? :)

•

Klein-Anleger@Klein-Anleger

@Alpalaka Why abbreviated? Do you mean the trading hours? He wrote that it's because of the Australian stock exchange...

•

Leon@Investingyoung

@Alpalaka I'm sure I've already saved an hour in my life 😎🤠

•

Leon@Investingyoung

@Klein-Anleger he means because I wrote "jz"

•

Marcel@Mcl1991

@Investingyoung We're in the position of having to solve the problem with a lack of time. But you don't have to do it all the time👁👁👄👁

•

Klein-Anleger@Klein-Anleger

@Investingyoung @Alpalaka jz or nt these are quite common, accepted abbreviations 🤔😅

•

Leon@Investingyoung

@Klein-Anleger yes for people our age... 😂
(NO BOOMER SHAMING)

•

Alpalaka@Alpalaka

@Investingyoung Do you also have a short and long break in the morning?

••

Leon@Investingyoung

@Alpalaka yes, according to my employment contract, I have a 30-minute breakfast break and lunch break 😁

•

Raketentoni@Raketentoni

Moin Leon, cool pick and strong numbers you dug up there! The margins of Pro Medicus (PME) really are out of this world. But let's get the facts straight for a moment: You call PME an "Australian smallcap" - have you looked at its market capitalization? It currently weighs over AUD 14 billion (approx. EUR 8.8 billion). This is an absolute heavyweight in the Australian ASX index and definitely no longer a small cap! 😉
As far as the spread is concerned, you're absolutely right: anyone adding Australian stocks (whether large or small cap) to their portfolio must be extremely careful between 7:30 and 8:00 a.m. European time (when the ASX is in its final hours of trading). A hard buy limit is an absolute must, otherwise the spread will directly eat away your first annual return. Together with Chugai and Hims & Hers, you have built a very aggressive but extremely exciting healthcare trio. Good luck with it!
🔬 Our internal analysis of Pro Medicus (ASX:PME)
Now it's getting serious. We are chasing the "treasure" through our filters at the current price of around AUD 133.55 (as at mid-March 2026).
The bare basic key figures
* Price-earnings ratio (P/E ratio): ~60.0 (yes, sixty!)
* Price-cash flow ratio (KCV): ~122.0
* Price-Sales Ratio (KUV): ~60.7
* Price-Book Value Ratio (KBV): ~37.5
* Dividend Yield: ~0.45
The acid test: The formulas
1. core quality formula (qualitative growth)
* Sales growth: ~30% (organic, through massive cloud contracts with US hospitals).
* Operating margin (EBIT): an insane 74 %.
* Score: 30 + 74 = 104
* Verdict: Absolutely disrupted (in a positive sense). The target of 25 is not just taken here, but shot to the moon. Pro Medicus is the absolute gold standard for software profitability. They have practically no competition that can keep up in terms of quality.
2. cash flow quality formula (the cash machine)
* Free cash flow (FCF): approx. 115 million AUD.
* FCF yield: AUD 115 million / AUD 14.5 billion (market cap) = ~0.8 %
* Verdict: Failed, BUT... An FCF yield of less than 1% misses your >5% hurdle by a wide margin. However, your exception rule applies exactly here: "Only allowed with crystal-clear growth". The growth is enormous and the cash flow is 100% genuine. The low yield is solely due to the incredibly expensive valuation of the share.
3. dividend filter (income core)
* Dividend yield: ~0.45 %
* Verdict: Exception approved. PME is completely useless for your classic dividend portfolio (target >= 3.5%). But your exceptions apply here too: Growth is brutal, the balance sheet is bulletproof (completely debt-free) and the dividend was recently raised by almost 40%. A pure growth satellite.
4. exclusion rules (red flags)
* Sales stagnating? No.
* Margin < 5 %? Nein. (Sie liegt bei 74 %!).
* Dividende nicht cashflow-gedeckt? Nein. (Ausschüttungsquote liegt bei sauberen 50 %).
* Story > figures? No. The story (AI in radiology) is big, but the numbers back it up perfectly.
📉 History: Why the share has been massively beaten up recently
If you look at the chart over the last few years, you'll see a perfect compounder that has multiplied. But be careful: In July 2025, the share was at AUD 336. A few weeks ago (end of February 2026) it crashed to AUD 107 and is now recovering slightly to AUD 133.
What was going on?
In summer 2025, the share was valued at a P/E ratio of well over 150. It was "priced for absolute perfection". When the half-year figures came out in February 2026 and sales had "only" risen by 28.4%, investors panicked. The company is fundamentally in absolute top form, but the market has burst the completely absurd valuation bubble ("multiple compression").
Conclusion for you
Pro Medicus is one of the best companies in the world in terms of quality. The score of over 100 speaks volumes. If you still have room in your portfolio for a pure, highly profitable growth satellite, the current level (P/E ratio 60 instead of 150) is much more attractive than it was a year ago.

•

Leon@Investingyoung

@Raketentoni Thank you for your comment 🙌🏼😁

Yes okay smallcap in the Australian sense maybe not but compared to all other stocks I meant 🫣😂

•

Raketentoni@Raketentoni

@Investingyoung I'd love to, nice spades but unfortunately nothing for my strategy 🤷

•

Leon@Investingyoung

@Raketentoni Which is perfectly fine

I like you guys, you're a real asset here 🙌🏼

My strategy is to go for full growth, but for some stocks with nice dividend growth I make an exception like $4519 and $COST which are growing okay but together with the divi it's good.

•

Raketentoni@Raketentoni

@Investingyoung oh thank you for the flowers 😬

•

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

Good value, I also have it on my screen.👍🏻

•

Leon@Investingyoung

@Get_Rich_or_Die_Tryin I now have 3 healthcare machines $HIMS $PME and the king $4519

I am happy with it

•

Keineui@Keineui

Perhaps $4568 is also of interest to you.

•

Leon@Investingyoung

@Keineui I don't know it, I'll take a look at the chart, it's attractive for now thanks

••

Leon@Investingyoung

@Keineui looks great, thanks 🙌🏼

I might have 4 pharma values soon, but first I have to expand my posis over the next 2-3 months

•

Ricola@Roccola601

I am also involved and really like the business model, and of course the share is not cheap, but in this case I think it is justified.

•

Leon@Investingyoung

@Roccola601 definitiv

••

Keineui@Keineui

Aktienfinder says: The fair value of the Pro Medicus share is calculated over the 10-year valuation period selected above. The average KCV in this case is 75.61.

Multiplied by the operating cash flow per share of AUD 1.30 over the last 4 quarters, this results in a fair value of AUD 98.29 for the Pro Medicus share. The current share price of AUD 133.54 is 35.9% above this fair value, which corresponds to an overvaluation of the share.

••

Leon@Investingyoung

@Keineui And now? I also bought palantir when it was overvalued, like almost all of my shares.

You pay for good things.

•